Biossil Inc.
Biotech startup that uses an AI platform to identify and develop discarded drug molecules for new therapies.
Canadian Venture (ON)
Biossil Repurposes Failed Drug Candidates Using Advanced AI Platform
The challenge of drug discovery has historically been defined by attrition. A molecule can show immense promise, only to fall through the rigorous gauntlet of preclinical and early clinical testing for reasons...
↗ Biossil leverages AI to solve the 'drug attrition' problem by repositioning discarded molecular candidates, drastically reducing the time and cost associated with early-stage drug development and offering a novel revenue stream from 'failed' scientific data.
Biossil Rethinks Drug Development: Mapping Therapeutics Through Semantic Vectors
The core strength of Biossil Inc. lies not in molecular engineering, but in its sophisticated application of natural language processing (NLP) to solve a systemic problem: the massive loss of therapeutic value...
↗ Biossil's innovation is a shift from molecular design (structure-based AI) to conceptual discovery (semantic AI), using LLMs to map latent therapeutic connections within the drug 'discard pile' using vector embeddings.